RealSeq Biosciences

RealSeq Biosciences, a biotechnology startup founded in 2019, has garnered interest with its groundbreaking RNA fragmentomics technology, demonstrating its commitment to being leaders in small RNA detection. The company's flagship product, RiboMarkers, represents the next generation of cell-free RNA fragmentomics-based diagnostics, offering dynamic reporting capabilities that can predict the dissemination of diseases in real-time. RealSeq is also focused on developing and commercializing a liquid biopsy platform tailored for debilitating fungal pathogens like Valley Fever, aiming to address the challenges associated with their management amidst their rapid spread, potentially exacerbated by factors such as climate change. The company's core expertise lies in the development of bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cell-free RNA analysis (liquid biopsy). RealSeq Biosciences recently secured a significant milestone with its Seed Round investment on 11 March 2024, attracting capital from notable investors, including Charleston Angel Partners, Santa Clara Ventures, and Santa Cruz Ventures. This funding is expected to further fuel the company's efforts in advancing its innovative technologies and bringing its pioneering solutions to the market. With its strong focus on cutting-edge research and development in the biotechnology sector, RealSeq Biosciences stands poised to make a meaningful impact on disease diagnosis and treatment.